CRT - Track Record About Us Who We Are What We Do What We Offer CRT Development Laboratories Drug Discovery Biotherapeutic Development Senior Scientists Scientific Advisory Board Case Studies Pipeline Strategic Alliances Development Funding Track Record Agents In Clinical Development Institutes & Charities Start-up Companies Press Releases 2006 2005 2004 2003 2002 2001 2000 Locations Vacancies Track...
BioPortfolio Limited 32 Some molecular markers have demonstrated prognostic utility regarding response to chemotherapy 34 CHAPTER 3 CURRENT TREATMENT OPTIONS 38 Supportive care 39 Surgical options for glioma patients 40 Radiotherapy options for glioma patients 41 Treatment of low-grade glioma 43 The ‘gold-standard’ treatment for low-grade glioma may be changing 44 No clinical benefit of...
BioPortfolio Limited Brain Metastases - Turning Prolonged Survival on its Head?
Database T T - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
Brochure40 page 4
author: james
Brochure40 page 4
author: james
Brochure40 page 4
author: james
Pediatric Exclusivity Labeling Changes Food and Drug Administration • Center for Drug Evaluation and Research Pediatrics Search Pediatric Exclusivity Labeling Changes as of February 6, 2004 - - Exclusivity Granted (Labeled) Product Indications Label Changes 1
http://www.fda.gov/cder/orange/appendix_a.txt 2, BUTABARBITAL SODIUM SARISOL, BUTABARBITAL SODIUM APPENDIX A PRODUCT NAME INDEX SATRIC, METRONIDAZOLE SCABENE, LINDANE SCANDONEST L, LEVONORDEFRIN SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE SCLEROSOL, TALC SCRUBTEAM SURGICAL SPONGEBRUSH, HEXACHLOROPHENE SEASONALE, ETHINYL ESTRADIOL SECOBARBITAL SODIUM, SECOBARBITAL SODIUM SECONAL SODIUM, SECOBARBITAL SODIUM SECREFLO, SECRETIN...
Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies Food and Drug Administration • Center for Drug Evaluation and Research Pediatrics Search Summaries of Medical and Clinical Pharmacology Reviews of Pediatric Studies as of January 28, 2004 Summaries of Medical and Clinical Pharmacology Reviews Drug Sponsor Review Summary Alendronate - Fosamax Merck Medical Clinical Pharmacology Atovaquone and Proguanil - Malarone- GlaxoSmithKline...
author: CDER Office of New Drugs
Report to the Nation: Drug Review Priority new drug approvals: Alitretinoin Amprenavir (2 dosage forms) Aspirin/extended release-dipyridamole Bexarotene Busulfan Caffeine citrate Cytarabine liposome Dalfopristin/quinupristin Epirubicin hydrochloride Ganirelix acetate Ketotifen fumarate Levonorgestrel Nedocromil sodium Nitric oxide Orlistat Oseltamivir phosphate Pemirolast potassium Pioglitazone hydrochloride...
author: OLIVERN
NMEs Approved in CY 1999 NMEs Approved in Calendar Year 1999 NDA Number Generic Name- Trade Name Dosage Form Applicant - --- Classification- Approval Date - - - - - - - 20-863 Cilostazol Pletal Tablet Otsuka Pharm 1S 01-15-1999 20-886 Alitretinoin Panretin Topical Gel Ligand Pharm 1-PV 02-02-1999 20-955 Sodium Ferric Gluconate Complex Ferrlicit Injectable R&D Labs 1P 02-18-1999 21-007 Amprenavir Agenerase...
author: Elaine Abraham
NDAs Approved under Subpart H NDAs Approved under Subpart H NDA # Trade Name Generic -Name Clock Date Approval Date AP Time Approval Basis Indication - - - - - - - - 20199 Hivid Zalcitabine 31-Oct-91 19-Jun-92 7.6 S Combination therapy with zidovudine in advanced HIV infection - - - - - - - - 50698 Biaxin Clarithromycin- 2-Nov-92 23-Dec-93 13.7 S Treatment of disseminated mycobacterial infections due to...
author: Darlene Norris
Microsoft Word - Approval.doc TEMODAR ® CAPSULES PAGE 1 SECTION 2 LABELING SCHERING- PLOUGH RESEARCH INSTITUTE F XXXXXXXX 1 2 PRODUCT 3 INFORMATION 4 5 TEMODAR ® 6 (temozolomide) 7 CAPSULES 8 9 DESCRIPTION 10 TEMODAR Capsules for oral administration contain temozolomide, an 11 imidazotetrazine derivativeTEMODAR 20 mg: brown imprint also contains pharmaceutical grade shellac...
author: BRADLEYS
Microsoft Word - Approval.doc page 2
author: BRADLEYS
duplicates:http://www.fda.gov/cder/foi/label/2003/21029se8-005_temodar_lbl.pdf
21029_Temodar.htm Temodar (Temozolomide) Capsules Food and Drug Administration • Center for Drug Evaluation and Research Approval Package [http://internet-dev/cder/templates/2ndrow-component.htm] [http://internet-dev/cder/templates/sidebar-component.htm] Temodar (Temozolomide) Capsules Company:- Schering Corporation Application No.:- 021029 Approval Date:-8/11/99 - Approval Letter(s) & Final Printed Labeling (2.5 MB...
author: Paul Stauffer
Quark.PDF page 13
author: default
C:\Documents and Settings\zajiceka\Desktop\2003 Reviews\temozolomid\ e\Temozolomide execsum BPCA.doc page 1
author: Anne Zajicek
C:\Data\NDA\Excutive Summary Clinical Review for NDA 21.doc Executive Summary Section Page 1 CLINICAL REVIEW Clinical Review for NDA 21- 029 Executive Summary This multidisciplinary medical- statistical review addresses a supplement to NDA 21- 029/ S- 005 for use of Temodar for the treatment of pediatric patients with recurrent malignant brain tumors
author: Alla Shapiro
C:\Data\NDA\Excutive Summary Clinical Review for NDA 21.doc page 2
author: Alla Shapiro
Microsoft Word - Approval.doc TEMODAR ® CAPSULES PAGE 1 SECTION 2 LABELING SCHERING- PLOUGH RESEARCH INSTITUTE F XXXXXXXX 1 2 PRODUCT 3 INFORMATION 4 5 TEMODAR ® 6 (temozolomide) 7 CAPSULES 8 9 DESCRIPTION 10 TEMODAR Capsules for oral administration contain temozolomide, an 11 imidazotetrazine derivativeTEMODAR 20 mg: brown imprint also contains pharmaceutical grade shellac...
author: BRADLEYS
http://www.fda.gov/cder/foi/label/2002/21029slr004lbl.pdf F- 22487825 PRODUCT INFORMATION TEMODAR ® (temozolomide) CAPSULES DESCRIPTION TEMODAR Capsules for oral administration contain temozolomide, an imida zotetrazine derivativeTEMODAR, patients receiving TEMODAR should...
http://www.fda.gov/cder/foi/label/2002/21029slr004lbl.pdf page 2
http://www.fda.gov/cder/foi/label/2002/21029slr004lbl.pdf page 1
Prescription and OTC Drug Product List 8/1999 RTU IN PLASTIC CONTAINER - DLT - MAR 19, 1999 - ADD - AP + BAXTER HLTHCARE 500MG/100ML N18657 001 - DLT - AP + SCS 500MG/100ML N18657 001 LORACARBEF MINOCYCLINE HYDROCHLORIDE CAPSULE; ORAL LORABID CAPSULE; ORAL - ADD - KING PHARMS 200MG N50668 001 - DLT - MINOCYCLINE HCL - ADD - DEC 31, 1991 - DLT - AB WARNER CHILCOTT EQ 50MG BASE N63066 001 - ADD - + 400MG N50668 002 - DLT - AUG 14,...
